Sinovac PCV13
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06183216 | Jan 2024 → Mar 2025 | pneumococcal infection | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07832500 | Sep 2026 → Mar 2027 expected | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07593924 | May 2026 → Jul 2027 expected | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06617715 | Oct 2024 → May 2026 overdue | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-20 | CanSino Biologics Inc. | CanSinoBIO Obtained NDA Approval for its 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine iPneucia® cansinotech.com ↗ |
| 2019-01-02 | CanSino Biologics Inc. | CanSinoBio Submitted Clinical Trial Application of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）to NMPA cansinotech.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sinovac PCV13 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07832500 ↗ |
| Known as | 13-valent Pneumococcal Polysaccharide Conjugate Vaccine | “A phase IIIb clinical trial of the study of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd (Sinovac) will be...” NCT07832500 ↗2“A phase 1b clinical trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd” NCT06183216 ↗ “13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd” NCT07593924 ↗ |
| Known as | PCV13 | “A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months...” NCT06617715 ↗3“A Phase IIIb clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 to 5 years.” NCT07832500 ↗ “A phase 1b clinical trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd” NCT06183216 ↗ “13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd” NCT07593924 ↗ |
| Modality | Vaccine | “13-valent Pneumococcal Polysaccharide Conjugate Vaccine” NCT06183216 ↗ |
| Route | Intramuscular | “Route of administration is intramuscular injection” NCT06183216 ↗ |